You are here

Articles

UK CML Patient Conference 2018 (22 Sept): Registration Now Open

published: 14 August 2018

Chronic myeloid leukemia and pregnancy: patient and partner perspectives

published: 29 July 2018

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors

published: 9 July 2018

Early Results of Lower Dose Dasatinib (50 mg Daily) as Frontline Therapy

published: 5 May 2018

Help CML Support by registering with AmazonSmile

published: 1 March 2018

Dasatinib dose management for the treatment of chronic myeloid leukemia

published: 28 February 2018

Long-Term Outcome Of Nilotinib 400 Mg Twice Daily In First-Line Treatment

published: 27 February 2018

Considerations for Successful Treatment-free Remission

published: 22 February 2018

Pancreatic enzyme elevation in patients treated with nilotinib

published: 20 February 2018

Once a day nilotinib: A Real Life Observational Study

published: 22 December 2017

CAR T Cells: Engineering a patient's immune cells to treat their cancer

published: 2 November 2017

Targeted Antibiotic Use May Help Cure Chronic Myeloid Leukaemia

published: 21 September 2017

In Memoriam: Tessa Holyoake

published: 9 September 2017

Stopping Drug Therapy for CML: EURO-SKI Results

published: 29 July 2017

Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients

published: 29 July 2017

Striving to vanquish leukaemia: Combination of two compounds shows promise in the lab

published: 20 July 2017

Treatment-free remission following frontline nilotinib in patients with CML in chronic phase: results from the ENESTfreedom study

published: 8 July 2017

Natural Killer Cell Counts Are Associated With Molecular Relapse-Free Survival After Imatinib Discontinuation

published: 10 June 2017

Maternal, Fetal, and Neonatal Imatinib Levels With Treatment of Chronic Myeloid Leukemia in Pregnancy

published: 13 May 2017

Strategies for Stopping TKIs Growing Clearer

published: 2 April 2017